PTC Therapeutics to Acquire Censa Pharmaceuticals
May 6, 2020
PTC Therapeutics has entered into an agreement to acquire Censa Pharmaceuticals to obtain CNSA-001 (sepiapterin), a Phase 3–ready oral therapy for phenylketonuria (PKU) and other BH4-pathway disorders. Under the deal PTC will pay approximately $10 million cash upfront and up to 850,000 shares of PTC common stock, plus potential development, regulatory and sales milestones totaling hundreds of millions of dollars.
- Buyers
- PTC Therapeutics, Inc.
- Targets
- Censa Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Processa Pharmaceuticals Acquires Vidya Therapeutics and Raises ~$200M for VT-7208 Phase 2 Programs
July 31, 2026
Biotechnology
Processa Pharmaceuticals acquired Vidya Therapeutics in a stock-for-stock transaction to bring Vidya’s CNS-penetrant, once-daily BTK inhibitor VT-7208 into Processa’s pipeline. Concurrently, Processa entered into a definitive agreement for an approximately $200 million private placement, with proceeds intended to fund VT-7208’s parallel Phase 2 proof-of-concept studies across food allergy, chronic spontaneous urticaria (CSU), and relapsing multiple sclerosis (RMS).
-
Neurocrine Biosciences to Acquire Celeno Therapeutics
April 7, 2026
Healthcare Services
Neurocrine Biosciences entered into a definitive all-cash agreement to acquire Celeno Therapeutics for approximately $2.9 billion. The deal is structured as a tender offer and is expected to close within ~90 days, subject to Hart-Scott-Rodino antitrust clearance and a majority of Celeno shares being tendered.
-
XenoTherapeutics Acquires ESSA Pharma
October 9, 2025
Pharmaceuticals
ESSA Pharma Inc.’s securityholders approved the acquisition of all issued and outstanding common shares of ESSA by XenoTherapeutics Inc. via a statutory plan of arrangement. The transaction is subject to Supreme Court of British Columbia approval and other customary closing conditions, with an expected court hearing on October 7, 2025 and completion around October 9, 2025.
-
Otsuka Pharmaceutical Acquires Jnana Therapeutics
August 1, 2024
Biotechnology
Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.
-
Lantheus Holdings Acquires Cerveau Technologies
February 6, 2023
Pharmaceuticals
Lantheus Holdings, Inc. acquired Knoxville-based Cerveau Technologies, Inc., gaining MK-6240, a clinical-stage F-18 PET imaging agent that targets Tau tangles in Alzheimer's disease. The stock purchase includes upfront and potential milestone payments plus royalty obligations and will expand Lantheus' radiopharmaceutical diagnostic imaging pipeline and research collaborations.
-
Shionogi Acquires Tetra Therapeutics
May 26, 2020
Biotechnology
Shionogi & Co., Ltd. agreed to acquire clinical-stage biopharmaceutical company Tetra Therapeutics, giving Shionogi global rights to Tetra's portfolio including BPN14770. The deal, announced May 26, 2020, is valued at up to $500 million in milestone and contingent payments.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.